AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $8.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $200K to $500K in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$8.7M netNet selling
- CongressSTOCK Act, last 180 days
- -$200K to -$500K netNet selling
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 4 cutMore cutting
Key stats
Fundamentals Sep 30- Open
- $86.63
- 52-wk high
- $92.59
- High
- $87.03
- 52-wk low
- $54.11
- Low
- $85.24
- Prev close
- $86.68
- Mkt cap
- $32.69B
- P/E
- 34.3x
- Volume
- 2.92M
- Fwd P/E
- 28.3x
- Beta
- 1.42
- P/S
- 6.6x
- P/B
- 12.6x
- Profit margin
- +20.1%
- Op margin
- +24.3%
- ROE
- +38.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about DXCM filings
Are insiders buying or selling DexCom Inc (DXCM) stock?
Net selling: insiders sold $8.7M and bought $0 of DXCM stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $8.7M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Sayer, Kevin R (Executive Chair), who sold $6.4M. The latest filing was on Sep 30, 2026.
Which members of Congress have traded DXCM recently?
Sen. Tina Smith (D) sold $100K to $250K on May 7, 2026, disclosed 3 days later. Sen. Tina Smith (D) sold $100K to $250K on Apr 29, 2026, disclosed 11 days later. In total, 1 member disclosed 2 DXCM trades with trade dates in the last 180 days, filed a median 7 days after trading.
How current is this DXCM smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Sells/Trims (3)
- MI
Millennium
$75.2M
trimmed
- SQ
Squarepoint
$71.3M
trimmed
- TS
Two Sigma
$66.9M
trimmed
What insiders are doing
What Congress is doing
Buys (1)
Sells (2)
How top traders are positioned
No tracked top-trader positions in DXCM right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 14.8% above what analysts expected.
Earnings per share
$0.61 expected
Reports Oct 29, 2026, in 28 days
Estimates as of Sep 30, 2026
EPS expected
$0.62 to $0.72
Revenue expected
24 analysts
Last 30 days
Analysts cutting estimates
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.21B | $1.26B | $1.19B | $1.31B |
| Cost of what it sold | $477.9M | $466.9M | $441.6M | $478.4M |
| Gross profit | $731.4M | $792.7M | $750.3M | $830.0M |
| What it spent | ||||
| Research and development | $157.5M | $148.2M | $145.3M | $153.0M |
| Sales and admin | $331.4M | $321.5M | $349.7M | $358.7M |
| Total operating expenses | $488.9M | $469.7M | $495.0M | $511.7M |
| What was left | ||||
| Operating profit | $242.5M | $323.0M | $255.3M | $318.3M |
| Interest on debt | $4.7M | $4.2M | $3.1M | $3.0M |
| Profit before tax | $352.3M | $340.7M | $269.5M | $317.5M |
| Tax | $68.5M | $73.4M | $70.0M | $68.4M |
| Net profit | $283.8M | $267.3M | $199.5M | $249.1M |
| EBITDA | $420.6M | $410.1M | $339.7M | $388.7M |
Technicals
Price structure
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage leans bullish
Abbott Laboratories (ABT) stock price, news, quote and history
Leans bullishSep 29Dexcom stock last trades at USD 86.68 on September 28, 2026
Leans bullishSep 28Dexcom Data Points to a CGM Awareness Gap, and Room to Grow
BullishSep 28Tandem Diabetes Expands Insulin Delivery System to 12 New Countries
NeutralSep 28The Insider Report: The Leaders Have Taken Off
BullishSep 28Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
NeutralSep 28DexCom stock reports 13.1 percent revenue growth at USD 86.62
BullishSep 28MEDS Stock Rockets As DataMEDS AI Bets Big On Cancer Diagnostics
Leans bullishSep 28
Macro
22 macro signals shaping DXCM right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results